15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Milestone Pharmaceuticals Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $7.00 to $8.00, so the covering firms are broadly aligned. The average target of $7.67 sits 585% above the current $1.12. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Milestone Pharmaceuticals Inc.
As of Jul, 3 of 3 firms rate MIST a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MIST EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.26 – $-0.18 · 4 analysts · +75% YoY
Next period, 4 analysts expect Milestone Pharmaceuticals Inc to earn $-0.21 a share (range $-0.26 – $-0.18), versus $-0.12 a year earlier. Full-year consensus is $-0.83, growing to $-0.91 the year after.
REVENUE · NEXT QUARTER
$1.6M
Range $500.0K – $2.0M · 4 analysts
Revenue is expected to reach $1.6M (range $500.0K – $2.0M). Full-year consensus is $5.4M, rising to $25.1M next year.
Top analysts covering Milestone Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MIST.
#1
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$10.00+792.9% to target
Overall win rate
35%
+ Follow
#2
Mohit Bansal
Wells Fargo
Buy
$7.00+525.0% to target
Coverage
—
+ Follow
#3
BF
Brandon Folkes
HC Wainwright & Co.
Buy
$8.00+614.3% to target
Coverage
—
+ Follow
#4
TF
Tiago Fauth
Raymond James
Buy
$6.00+435.7% to target
Coverage
—
+ Follow
#5
Ritu Baral
TD Cowen
Buy
$8.00+614.3% to target
Coverage
—
+ Follow
MIST stock forecast FAQ
What is MIST's average 12-month price target?+
The 3 analysts with a live target average $7.67 for Milestone Pharmaceuticals Inc over the next 12 months, ranging from a $8.00 high to a $7.00 low.
Is MIST stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MIST?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $7.00 (Wells Fargo). The average of all 3 active targets is $7.67.
How many Wall Street analysts cover MIST?+
3 analysts have an active rating on Milestone Pharmaceuticals Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering MIST?+
Among analysts who currently cover MIST, Patrick R. Trucchio of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #203). Their current call is Buy with a $10.00 target.
What is Milestone Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.26 – $-0.18) across 4 analysts. Full-year EPS is projected at $-0.83, rising to $-0.91 the following year.
How much revenue is Milestone Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $1.6M (range $500.0K – $2.0M). Full-year revenue is projected at $5.4M, growing to $25.1M next year.
Have analysts been upgrading or downgrading MIST lately?+
As of Jul, 3 of 3 firms rate MIST a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MIST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
